Hansa Biopharma

Hansa Biopharma is a commercial-stage biopharmaceutical company focused on developing and commercializing immunomodulatory treatments for rare and severe immunoglobulin G (IgG)-mediated conditions. The company's proprietary technology platform utilizes IgG-cleaving enzymes, specifically imlifidase, to rapidly and effectively inactivate pathogenic antibodies. This approach is particularly transformative in enabling kidney transplantations for highly sensitized patients who would otherwise remain on long-term dialysis. Beyond transplantation, Hansa is expanding its pipeline into acute autoimmune diseases, gene therapy, and oncology. Its next-generation enzyme, HNSA-5487, is designed for lower immunogenicity to allow for repeat dosing in chronic conditions. The company operates globally with a strong presence in Europe and the United States, leveraging partnerships with major biotech firms to integrate its enzyme technology into broader therapeutic regimens.